About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

Nice one Driver! Confirms our opinion that the company is "extremely undervalued at the moment" Couldn't be happier to be in right now!
kim

A nice 18% rise this morning that's more like it.

PORTFOLIO REVIEW Last updated: 23/02/06

Billam AG have reviewed the Technical Portfolio of EiRx Therapeutics plc and detail it as follows:

ALIBI genomics discovery platform (2 patents, plus skills and know-how in genomics and cell biology)

Patents on 100+ potential drug targets in apoptosis and tumour cell survival pathways

OSI Pharmaceuticals license agreement milestones of up to $4.9M per target

siRNA technology liposomal delivery vector and panel of 60+ tumour cell lines in 15 phenotypic and functional assays

EnPAD technology skills and know-how in engineering cellular drug screening model

EnPAD -catenin cell line (+ EnPAD PI3K/Akt cell line in development Q1 06)

Pyrazolopyrimidine patent new family of potential drug compounds targeting catenin signalling

2-aminopyridine patent new family of potential drug compounds targeting -catenin signalling

Marie Curie grant programme approx. 400,000 left to draw down

Exclusive commercial license to Aberdeen Colorectal Tissue Bank

Colorectal cancer markers patent on 11 proteins from proteomic study

Cytochrome P450 1B1 intellectual property (3 patents covering diagnostic, therapeutic use)

MGI Pharma license agreement ($100,000 at Phase II, $250,000 at Phase III, $0.5M at NDA, 2% of net sales or 8.5% of sublicense income.

Cytochrome P450 patent 5 more proteins over-expressed in tumours

CYP51 inhibitor project

ArraDx collaboration - 200,000 to come from InterTrade Ireland INNOVA grant


http://www.billamag.net/focus-text-main-quoted.asp?FocusTextID=33

Nice bit of news today.

CANCER COLLABORATION WITH BIOMERIEUX SA


Cork, Ireland - EiRx Therapeutics plc (AIM: ERX), the drug discovery company
developing targeted therapies for cancer, is pleased to announce that it has
entered into a collaboration agreement with bioMerieux SA, the leading
international diagnostics group headquartered in Marcy l'Etoile, France. Under
the terms of the agreement, the companies will work together to validate the
diagnostic and therapeutic potential of candidate tumour markers emerging from
their respective cancer research programmes.

http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html

BioMieux is present in over 130 countries, with more than 100 distributors and 33 subsidiaries, and continues its international development.


Biomerieux Web Site is in the header.

300k+ trade gone through thats large in my book. Up 37% looking good.

excellent news but revenues still seem a long way off!

mp
Never mind the revenues the deal they done with this company is huge for such a tiddler as erx we can see this going to 1p and beyond in the next week or so.

just checked ADVN-a lot of comment over there to bring even more of a smile. 6 billion euros announced by the gov. in Eire for science and tech. development-eirx will be a beneficiary. they also have a rumoured Danish deal-more to be announced soon but the company is pleased with the market reaction so far. onwards and upwards!!

welcome back driver,well done on erx

Cheers plm are you in it's not to late.

i bought 1 month ago, i was getting impatient,

plm
You shouldnt get impatient with these stocks as with oil, just sit and accumulate and wait. And hope of coarse.

you are right i have been in blr since march they are back to what i paid for,but you know i dont collect shares i want a quick profit i do not beleive in tomorrow
remember ult i bought at 0.30/0.32 and sold at 1.36 1.25m that was a good one
look what they are now a year later since ult i bought and sold 20 shares paper profit is no good to me,i like it in the bank....................................................

Shares in EiRx Therapeutics jumped 0.09p to 0.275p after the group unveiled a collaboration agreement with French group bioMerieux. Under the terms of the agreement, the companies will work together to validate the diagnostic and therapeutic potential of candidate tumour markers emerging from their respective cancer research programmes. Both EiRx and bioMerieux undertake research into the expression of genes and proteins within tumour samples from cancer patients, aiming to identify biomarkers associated with the development and progression of the disease.

I think we are going to see a lot of news flow this year and an sp to match.

Notable milestones in 2005/6 include:

Acquisition of oncology company Auvation Ltd

Collaborative research agreement with Merck & Co. Inc. to evaluate EiRx's siRNA delivery technology

Award of a Marie Curie Programme grant from the European Commission, to support development of the company's screening, chemistry and efficacy testing capabilities

Development of the EnPADTM drug screening technology to enable identification of compounds that specifically target cell survival pathways

Filing of patent applications on first series of potential anti-cancer compounds identified using EnPADTM, which target the b-catenin signalling pathway to selectively kill colorectal and breast cancer cells in vitro

Filing of patent application describing a second series of potential anti-cancer compounds identified using EnPADTM

1.2M raised by issue of new shares on 31st March 2006

12th July 2006
CANCER COLLABORATION WITH BIOMERIEUX SA

Director Retires
http://moneyam.uk-wire.com/cgi-bin/articles/200607191251134380G.html

This is a long-term hold or is it.

The company is very much under valued and will very soon be producing compounds that will have an impact on the value of the company. Its all in the interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real

sounds a very committed and sincere CEO - I'm convinced the potential is on the brink of something big. They could do with a bit of PR coaching though when doing these interviews with the yanks it sounds a bit heavy.

ERX on the up punters are hoping for some news Im sure we will see some before the end of the year.